Filing Flows › Regenerative Medical Technology Group (RMTG) › Q1 2026 › vs Q1 2025
Regenerative Medical Technology Group (RMTG) Q1 2026 vs Q1 2025 (year over year)
Regenerative Medical Technology Group's revenue rose $1.3M (+93%) from $1.4M in Q1 2025 to $2.6M in Q1 2026. The biggest changes: Product Supplies +$640K (+102%); Training +$627K (+433%); Patient Procedures +$8K (+1%).
Regenerative Medical Technology Group, Q1 2026: revenue $2.6M (+94% year over year), operating margin 8.7%, net loss $876K, operating cash flow $102K. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product Supplies | $1.3M | $627K | $640K | +102% |
| Training | $772K | $145K | $627K | +433% |
| Patient Procedures | $600K | $593K | $8K | +1% |
| Revenue | $2.6M | $1.4M | $1.3M | +93% |
| Net loss | $876K | $760K | $116K | +15% |
| Costs & expenses | $3.5M | $2.1M | $1.4M | +65% |
| Operating costs | $2.4M | $1.2M | $1.2M | +96% |
| Interest & other, net | $1.1M | $895K | $211K | +24% |
| Cost of revenue | $873K | $420K | $452K | +108% |
| Sales & marketing | $391K | $157K | $234K | +149% |
| General & admin | $476K | $246K | $230K | +94% |
| Other operating costs | $670K | $406K | $264K | +65% |
| Operating cash sources | $978K | $817K | $161K | +20% |
| Depreciation & amortization | $98K | $52K | $46K | +89% |
| Working capital & other | $881K | $765K | $115K | +15% |
| Net loss absorbed | $876K | $760K | $116K | +15% |
| Operating cash flow | $102K | $57K | $45K | +79% |
Questions
How much did Regenerative Medical Technology Group's revenue grow year over year in Q1 2026?
Regenerative Medical Technology Group's revenue rose $1.3M (+93%) from $1.4M in Q1 2025 to $2.6M in Q1 2026.
What drove Regenerative Medical Technology Group's revenue change in Q1 2026?
Product Supplies +$640K (+102%); Training +$627K (+433%); Patient Procedures +$8K (+1%).